Interleukin 2-mediated Conversion of Ovarian Cancer-associated CD4+ Regulatory T Cells Into Proinflammatory Interleukin 17-producing Helper T Cells
暂无分享,去创建一个
K. Odunsi | L. Old | D. Valmori | L. Leveque | M. Ayyoub | F. Deknuydt | G. Bioley | Junko Matsuzaki
[1] P. Muranski,et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.
[2] K. Odunsi,et al. Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. , 2008, Clinical immunology.
[3] H. Ueno,et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma , 2007, Proceedings of the National Academy of Sciences.
[4] A. Melcher,et al. Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. , 2007, Cancer research.
[5] Graham M Lord,et al. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes , 2007, Proceedings of the National Academy of Sciences.
[6] F. Legendre,et al. Interleukin-1β impairment of transforming growth factor β1 signaling by DOWN-REGULATION of transforming growth factor β receptor type II and up-regulation of Smad7 in human articular chondrocytes , 2007 .
[7] L. Cosmi,et al. Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.
[8] F. Sallusto,et al. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells , 2007, Nature Immunology.
[9] M. Banerjee,et al. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. , 2007, Cancer research.
[10] Terry B. Strom,et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells , 2007, Nature.
[11] E. Shevach,et al. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. , 2007, Blood.
[12] A. Fader,et al. Role of surgery in ovarian carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Strober,et al. Cutting Edge: Regulatory T Cells Induce CD4+CD25−Foxp3− T Cells or Are Self-Induced to Become Th17 Cells in the Absence of Exogenous TGF-β , 2007, The Journal of Immunology.
[14] A. Chang,et al. Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment1 , 2007, The Journal of Immunology.
[15] L. Hennighausen,et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. , 2007, Immunity.
[16] K. Murphy,et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.
[17] H. Weiner,et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.
[18] D. Gabrilovich,et al. Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer , 2006, Cancer Immunology, Immunotherapy.
[19] R. J. Hocking,et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.
[20] K. Odunsi,et al. Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells , 2006, Clinical Cancer Research.
[21] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[22] I. Fidler,et al. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. , 2005, Cancer research.
[23] D. Valmori,et al. A peripheral circulating compartment of natural naive CD4 Tregs. , 2005, The Journal of clinical investigation.
[24] J. Metcalf,et al. In vivo expansion of CD4+CD45RO–CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients , 2005 .
[25] E. Tartour,et al. Expression and activity of IL‐17 in cutaneous T‐cell lymphomas (mycosis fungoides and sezary syndrome) , 2004, International journal of cancer.
[26] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[27] L. Cosmi,et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. , 2004, Blood.
[28] Li Li,et al. Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.
[29] Yao-Tseng Chen,et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. , 2003, Cancer research.
[30] M. Lotze,et al. Interleukin-17 promotes angiogenesis and tumor growth. , 2003, Blood.
[31] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[32] E. Tartour,et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. , 2002, Blood.
[33] Sayuri Yamazaki,et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.
[34] K. Yamasawa,et al. Inoculation of Human Interleukin-17 Gene-Transfected Meth-A Fibrosarcoma Cells Induces T Cell-Dependent Tumor-Specific Immunity in Mice , 2001, Oncology.
[35] M. Irahara,et al. Expression of IL-17 mRNA in ovarian cancer. , 2001, Biochemical and biophysical research communications.
[36] D. Speiser,et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. , 2000, Cancer research.
[37] L. Levy,et al. Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] J. Banchereau,et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. , 1999, Cancer research.
[39] J. Kirkwood,et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] F. Legendre,et al. Interleukin-1beta impairment of transforming growth factor beta1 signaling by down-regulation of transforming growth factor beta receptor type II and up-regulation of Smad7 in human articular chondrocytes. , 2007, Arthritis and rheumatism.
[41] F. Sallusto,et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.
[42] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[43] J. Metcalf,et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. , 2005, The Journal of clinical investigation.
[44] E. Shevach,et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.
[45] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.